The story of the rare disease market in recent years has been centered around growth with large pharmas starting to see more promise in the space as deals tick up. Explore the latest developments in
this Trendline.
HHS Secretary Robert F. Kennedy Jr. has said that federal health agencies are riddled with conflicts of interest. During confirmation hearings, he insisted that 97% of the CDC’s Advisory Committee on Immunization Practices had ties to the industry, referring to a government report from 2009. A former CDC director from that time told NPR the statement was “a total misrepresentation of a 20-year-old report, about a process that was already being improved before that report was issued.”
Whether or not Kennedy is cherry-picking decades-old data to set the stage for an HHS MAHA makeover, the message to the industry and its regulators is clear: Don’t let the revolving door hit you on the way out. The problem is, which healthcare experts are left to do the work when those with experience in both industry and government are excluded from the conversation?
Meanwhile, conflicts of interest remain a major concern among the Trump administration’s own ranks — consider the president’s global business holdings in hotels, golf courses, merchandise and more, or how Elon Musk has slashed federal programs while leaving government contracts with his companies intact.
Kennedy’s own conflicts of interest, including the millions he’s made from lawsuits against vaccine makers, peppered his confirmation hearings. And now, Kennedy’s conflicts are once again in the spotlight. Today, we’re exploring lawmakers’ recent request for details surrounding high-level Mar-a-Lago meetings between Kennedy, President Trump and top pharma executives — and what they could mean for the direction of the federal health agency.
Thanks for reading.
Michael Gibney Senior Editor & Writer, PharmaVoice Email
HHS head Robert F. Kennedy Jr. has long been an opponent of pharma influence in government. U.S. lawmakers are asking whether unofficial Mar-a-Lago meetings point to a change of heart.
Labs are under increasing pressure to process more samples while facing ongoing workforce challenges. Explore the tactics top labs use to successfully adopt automation, boost efficiency and maximize ROI in this playbook.
The rundown from yesterday
Yesterday, we looked at potential reforms to the IRA under the new Trump administration, which so far has left the healthcare provisions untouched.
PharmaVoice readers who believe more transparency in the U.S. healthcare system would help reduce prices for consumers. Just 20% said it wouldn't help.
Pharma is increasingly embracing AI as studies showcase its potential for drug discovery, clinical trials and prescribing practices. Learn how tech is changing life sciences in this Trendline.